FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	/AL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)													
1. Name and Address of Reporting Person * TYLE PRAVEEN				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner						
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 02/01/2019						Officer (giv	e title below)	Oth	er (specify belo	ow)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
WALIH (Cit	AM, MA (J2452 (State)	(Zip)	Table I - Non-Derivative Securities Acqui											
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Day (Month/Day/		Date, if (8) (A. Securities Acca A) or Disposed Instr. 3, 4 and 5 (A) or (D)	of (D)	5. Amount of S Owned Follow Transaction(s) (Instr. 3 and 4)	Securities Beneficially wing Reported		Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder:	Report on a s	eparate line for each		- Derivati	ive S	Securities	s Acq	Persor in this display uired, Disp	s who responds are not by a currently cosed of, or Benonvertible secu	required valid O	d to respond MB control r	unless the		ed SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	ercise (Month/Day/Year) of ative	3A. Deemed Execution Date, if	4. Transaction Code (Instr. 8)		5. Number		6. Date Exe Expiration (Month/Da	ercisable and Date	7. Title of Und Securit	e and Amount derlying ties 3 and 4)		9. Number o Derivative Securities Beneficially Owned Following Reported Transaction(Ownersh Form of Derivativ Security: Direct (E or Indirect	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 0.48	02/01/2019		A		50,000)	(1)	02/01/2029	Comi	150 000	\$ 0	50,000	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
TYLE PRAVEEN C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	X						

Signatures

/s/ Robert A. Petitt, Attorney-in-Fact, Signed under power of attorney on behalf of Reporting Person	02/05/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.